Immune cells engineered to fight lupus enter first human tests

NCT ID NCT07358988

Not yet recruiting Disease control Sponsor: Ruitherapeutics Co., LTD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new treatment called KN5501 for people with moderate to severe lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) to target and destroy faulty B cells that drive the disease. Participants will receive one or more infusions after a short chemotherapy-like prep, and researchers will monitor safety, side effects, and whether lupus activity decreases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERTHEMATOSUS (SLE)

Contacts and locations

Locations

Bengbu Medical College First Affiliated Hospital

Bengbu, Anhui, China
Changhai Hospital of Shanghai

Shanghai, Shanghai Municipality, China
Jiangsu Provincial People's Hospital

Nanjing, Jiangsu, China
Peking Union Medical College Hospital

Beijing, Beijing Municipality, China
The First Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.